Skip to main content
Erschienen in: Medical Molecular Morphology 1/2017

23.06.2016 | Original Paper

Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy

verfasst von: Masakazu Hori, Masanori Someya, Yoshihisa Matsumoto, Kensei Nakata, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yasushi Sato, Hiroyuki Ohnuma, Junji Kato, Shintaro Sugita, Tadashi Hasegawa, Koh-Ichi Sakata

Erschienen in: Medical Molecular Morphology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

DNA double-strand break (DSB) is one of the most serious forms of damage induced by ionizing irradiation and is mainly repaired by the non-homologous end joining (NHEJ) repair. Immunohistochemical analysis of proteins involved in NHEJ, such as XRCC4 (X-ray repair cross-complementing protein 4), Ku86 and DNA-PKcs (DNA-dependent protein kinase, catalytic subunits), may be useful for predicting tumor radiosensitivity. We examined 92 patients with esophageal squamous cell carcinoma (ECSS) who were treated by radiotherapy between 1999 and 2008. Immunohistochemical examination of tumor tissue for Ki-67 and DSB-related proteins, including XRCC4, Ku86, and DNA-PKcs, was performed using pretreatment biopsy specimens. Low expression of XRCC4 was detected in 31 of 92 examined samples (33.7 %). The 5-year overall survival (OS) rate was 67.7 % in the low expression group and 31.0 % in the high expression group (P = 0.00). Multivariate analysis confirmed that advanced T-stage (HR 3.24, P = 0.01), radiation dose less than 66 Gy (HR 2.23, P = 0.02), absence of systemic chemotherapy (HR 2.59, P = 0.05), and high expression of XRCC4 (HR 12.0, P = 0.02) were independent prognostic factors for predicting poor OS. Other DSB-related proteins and Ki-67 were not predictive factors. XRCC4 expression might have an influence on results of radiotherapy for patients with ESCC.
Literatur
1.
Zurück zum Zitat Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H, Japan Clinical Oncology Group (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol 21:4592–4596CrossRef Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H, Japan Clinical Oncology Group (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol 21:4592–4596CrossRef
2.
Zurück zum Zitat Udagawa H, Ueno M, Shinohara H, Haruta S, Kaida S, Nakagawa M, Tsurumaru M (2012) The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer. J Surg Oncol 106:742–747CrossRefPubMed Udagawa H, Ueno M, Shinohara H, Haruta S, Kaida S, Nakagawa M, Tsurumaru M (2012) The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer. J Surg Oncol 106:742–747CrossRefPubMed
3.
Zurück zum Zitat Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, Yoshida S, Nishimura M, Haruno M, Ishikura S, Ogino T, Yamamoto S, Ochiai A (2003) Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T2–3Nany M0 squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57:425–433CrossRefPubMed Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, Yoshida S, Nishimura M, Haruno M, Ishikura S, Ogino T, Yamamoto S, Ochiai A (2003) Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T2–3Nany M0 squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57:425–433CrossRefPubMed
4.
Zurück zum Zitat Blazeby MJ, Farndon RJ, Donovan J, Alderson D (2000) A Prospective Longitudinal Study Examining the Quality of Life of Patients with Esophageal Carcinoma. Cancer 88:1781–1787CrossRefPubMed Blazeby MJ, Farndon RJ, Donovan J, Alderson D (2000) A Prospective Longitudinal Study Examining the Quality of Life of Patients with Esophageal Carcinoma. Cancer 88:1781–1787CrossRefPubMed
5.
Zurück zum Zitat American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, List MA, O’Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT (2006) American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24:3693–3704CrossRef American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, List MA, O’Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT (2006) American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24:3693–3704CrossRef
6.
Zurück zum Zitat Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H (2009) Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 137:49–54CrossRefPubMed Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H (2009) Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 137:49–54CrossRefPubMed
7.
Zurück zum Zitat Hall EJ (2006) DNA strand breaks and chromosomal aberrations. In: Hall EJ, Giaccia AM (eds) Radiobiology for the Radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 16–29 Hall EJ (2006) DNA strand breaks and chromosomal aberrations. In: Hall EJ, Giaccia AM (eds) Radiobiology for the Radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 16–29
8.
9.
Zurück zum Zitat Kamdar RP, Matsumoto Y (2010) Radiation-induced XRCC4 association with chromatin DNA analyzed by biochemical fractionation. J Radiat Res 51:303–313CrossRefPubMed Kamdar RP, Matsumoto Y (2010) Radiation-induced XRCC4 association with chromatin DNA analyzed by biochemical fractionation. J Radiat Res 51:303–313CrossRefPubMed
10.
Zurück zum Zitat Okuno Y, Nishimura Y, Kashu I, Ono K, Hiraoka M (1999) Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas. Br J Cancer 80:387–395CrossRefPubMedPubMedCentral Okuno Y, Nishimura Y, Kashu I, Ono K, Hiraoka M (1999) Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas. Br J Cancer 80:387–395CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Sato Y, Takayama T, Sagawa T, Okamoto T, Miyanishi K, Sato T, Araki H, Iyama S, Abe S, Murase K, Takimoto R, Nagakura H, Hareyama M, Kato J, Niitsu Y (2006) A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. Cancer Chemother Pharmacol 58:570–576CrossRefPubMed Sato Y, Takayama T, Sagawa T, Okamoto T, Miyanishi K, Sato T, Araki H, Iyama S, Abe S, Murase K, Takimoto R, Nagakura H, Hareyama M, Kato J, Niitsu Y (2006) A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. Cancer Chemother Pharmacol 58:570–576CrossRefPubMed
12.
Zurück zum Zitat Someya M, Sakata K, Saito A, Nagakura H, Oouchi A, Hareyama M (2002) Results of external irradiation and low-dose-rate intraluminal brachytherapy for esophageal cancer. Acta Oncol 41:63–68CrossRefPubMed Someya M, Sakata K, Saito A, Nagakura H, Oouchi A, Hareyama M (2002) Results of external irradiation and low-dose-rate intraluminal brachytherapy for esophageal cancer. Acta Oncol 41:63–68CrossRefPubMed
13.
Zurück zum Zitat Hayashi J, Sakata K, Someya M, Matsumoto Y, Satoh M, Nakata K, Hori M, Takagi M, Kondoh A, Himi T, Hareyama M (2012) Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol Lett 4:151–155PubMedPubMedCentral Hayashi J, Sakata K, Someya M, Matsumoto Y, Satoh M, Nakata K, Hori M, Takagi M, Kondoh A, Himi T, Hareyama M (2012) Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol Lett 4:151–155PubMedPubMedCentral
14.
Zurück zum Zitat Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, Shimada H, Takiuchi H, Toh Y, Doki Y, Naomoto Y, Matsubara H, Miyazaki T, Muto M, Yanagisawa A (2015) Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus 12:1–30CrossRefPubMed Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, Shimada H, Takiuchi H, Toh Y, Doki Y, Naomoto Y, Matsubara H, Miyazaki T, Muto M, Yanagisawa A (2015) Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus 12:1–30CrossRefPubMed
15.
Zurück zum Zitat Tsuchimoto T, Sakata K, Someya M, Yamamoto H, Hirayama R, Matsumoto Y, Furusawa Y, Hareyama M (2011) Gene expression associated with DNA-dependent protein kinase activity under normoxia, hypoxia and reoxygenation. J Radiat Res 52:464–471CrossRefPubMed Tsuchimoto T, Sakata K, Someya M, Yamamoto H, Hirayama R, Matsumoto Y, Furusawa Y, Hareyama M (2011) Gene expression associated with DNA-dependent protein kinase activity under normoxia, hypoxia and reoxygenation. J Radiat Res 52:464–471CrossRefPubMed
16.
Zurück zum Zitat Hadjiliadis N (2009) Platinum drugs, nucleotides, and DNA: the role of inter ligand interactions, nucleotides and DNA. In: Hadjiliadis N, Sletten E (eds) Metal complex-DNA interactions. Wiley-Blackwell, USA, pp 174–209CrossRef Hadjiliadis N (2009) Platinum drugs, nucleotides, and DNA: the role of inter ligand interactions, nucleotides and DNA. In: Hadjiliadis N, Sletten E (eds) Metal complex-DNA interactions. Wiley-Blackwell, USA, pp 174–209CrossRef
17.
Zurück zum Zitat Beskow C, Kanter L, Holgersson A, Nilsson B, Frankendal B, Avall-Lundqvist E, Lewensohn R (2006) Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB–IIA of cervical cancer. Br J Cancer 94:1683–1689PubMedPubMedCentral Beskow C, Kanter L, Holgersson A, Nilsson B, Frankendal B, Avall-Lundqvist E, Lewensohn R (2006) Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB–IIA of cervical cancer. Br J Cancer 94:1683–1689PubMedPubMedCentral
18.
Zurück zum Zitat Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J (2008) Prognostic significance of Ataxia- Telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 112:2756–2764CrossRefPubMedPubMedCentral Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J (2008) Prognostic significance of Ataxia- Telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 112:2756–2764CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Söderlund Leifler K, Queseth S, Fornander T, Askmalm MS (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37:1547–1554PubMed Söderlund Leifler K, Queseth S, Fornander T, Askmalm MS (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37:1547–1554PubMed
20.
Zurück zum Zitat Someya M, Sakata K, Matsumoto Y, Satoh M, Narimatsu H, Hareyama M (2007) Immunohistochemical analysis of Ku70/86 expression of breast cancer tissues. Oncol Rep 18:1483–1487PubMed Someya M, Sakata K, Matsumoto Y, Satoh M, Narimatsu H, Hareyama M (2007) Immunohistochemical analysis of Ku70/86 expression of breast cancer tissues. Oncol Rep 18:1483–1487PubMed
21.
Zurück zum Zitat Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Tsuno N, Kazama S, Kitayama J, Suzuki N, Nagawa H (2002) The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer 95:1199–1205CrossRefPubMed Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Tsuno N, Kazama S, Kitayama J, Suzuki N, Nagawa H (2002) The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer 95:1199–1205CrossRefPubMed
22.
Zurück zum Zitat Master R, DePinho R (2002) Connecting chromosomes, crisis, and cancer. Science 297:565–569CrossRef Master R, DePinho R (2002) Connecting chromosomes, crisis, and cancer. Science 297:565–569CrossRef
23.
Zurück zum Zitat Dorr W (2009) Pathogenesis of normal-tissue side-effects. In: Joiner M, Van der Kogel A (eds) Basic clinical radiobiology, 4th edn. Hodder Arnold, UK, pp 169–190CrossRef Dorr W (2009) Pathogenesis of normal-tissue side-effects. In: Joiner M, Van der Kogel A (eds) Basic clinical radiobiology, 4th edn. Hodder Arnold, UK, pp 169–190CrossRef
Metadaten
Titel
Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy
verfasst von
Masakazu Hori
Masanori Someya
Yoshihisa Matsumoto
Kensei Nakata
Mio Kitagawa
Tomokazu Hasegawa
Takaaki Tsuchiya
Yuki Fukushima
Toshio Gocho
Yasushi Sato
Hiroyuki Ohnuma
Junji Kato
Shintaro Sugita
Tadashi Hasegawa
Koh-Ichi Sakata
Publikationsdatum
23.06.2016
Verlag
Springer Japan
Erschienen in
Medical Molecular Morphology / Ausgabe 1/2017
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI
https://doi.org/10.1007/s00795-016-0144-5

Weitere Artikel der Ausgabe 1/2017

Medical Molecular Morphology 1/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …